Drug · DIN 02562618
OZEMPIC
DISPENSES 0.25 MG OR 0.5 MG DOSES. MULTIDOSE PREFILLED PEN. 3 ML SOLUTION
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since November 4, 2025.
- Drug Identification Number (DIN)
- 02562618
- Company (DIN owner)
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Semaglutide A10BJ06
- Class
- Human
- Record last updated
- September 22, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SEMAGLUTIDE | 1.34 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 4, 2025: NOC 36344Supplement to a New Drug Submission (SNDS) · New presentation
Other DINs named OZEMPIC
- DIN 02471469 · Marketed
- DIN 02540258 · Marketed
- DIN 02471477 · Dormant
- DIN 02523930 · Approved
- DIN 02562626 · Approved